Targeted delivery of tumor necrosis factor-related apoptosis-inducing ligand to keratinocytes with a pemphigus mAb

Journal of Investigative Dermatology

Volumn 133, Issue 9, 2013, Pages 2212-2220

  Kouno, Michiyoshi ^a,b   Lin, Chenyan ^a   Schechter, Norman M ^a   Siegel, Don ^a   Yang, Xiaoping ^a   Seykora, John T ^a   Stanley, John R ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b KEIO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ENHANCED GREEN FLUORESCENT PROTEIN; GAMMA INTERFERON; PEMPHIGUS ANTIBODY; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BACULOVIRUS; CD4+ T LYMPHOCYTE; CELL SURFACE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; EPIDERMIS; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOFLUORESCENCE; KERATINOCYTE; LEUKEMIA CELL LINE; LYMPHOCYTE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SKIN; SKIN DISEASE; XENOGRAFT;

EID: 84884415516     PISSN: 0022202X     EISSN: 15231747     Source Type: Journal    
DOI: 10.1038/jid.2013.85     Document Type: Article

References (32)

1. Abdulghani J, El-Deiry WS (2010) TRAIL receptor signaling and therapeutics. Expert Opin Ther Targets 14:1091-108
2. Ashkenazi A, Pai RC, Fong S et al. (1999) Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest 104:155-62
3. Basile JR, Zacny V, Munger K (2001) The cytokines tumor necrosis factor-Alpha (TNF-Alpha) and TNF-related apoptosis-inducing ligand differentially modulate proliferation and apoptotic pathways in human keratinocytes expressing the human papillomavirus-16 E7 oncoprotein. J Biol Chem 276:22522-8
4. Berg D, Lehne M, Muller N et al. (2007) Enforced covalent trimerization increases the activity of the TNF ligand family members TRAIL and CD95L. Cell Death Differ 14:2021-34
5. Bremer E, Samplonius D, Kroesen BJ et al. (2004) Exceptionally potent anti-Tumor bystander activity of an scFv:sTRAIL fusion protein with specificity for EGP2 toward target antigen-negative tumor cells. Neoplasia 6:636-45
6. Bremer E, Samplonius DF, Peipp M et al. (2005) Target cell-restricted apoptosis induction of acute leukemic T cells by a recombinant tumor necrosis factor-related apoptosis-inducing ligand fusion protein with specificity for human CD7. Cancer Res 65:3380-8
7. Chen YJ, Chang JT, Lee L et al. (2007) DSG3 is overexpressed in head neck cancer and is a potential molecular target for inhibition of oncogenesis. Oncogene 26:467-76
8. de Bruyn M, Rybczynska AA, Wei Y et al. (2010) Melanoma-Associated chondroitin sulfate proteoglycan (MCSP)-Targeted delivery of soluble TRAIL potently inhibits melanoma outgrowth in vitro and in vivo. Mol Cancer 9:301
9. Elrod HA, Fan S, Muller S et al. (2010) Analysis of death receptor 5 and caspase-8 expression in primary and metastatic head and neck squamous cell carcinoma and their prognostic impact. PLoS One 5:e12178
10. Hirata S, Senju S, Matsuyoshi H et al. (2005) Prevention of experimental autoimmune encephalomyelitis by transfer of embryonic stem cellderived dendritic cells expressing myelin oligodendrocyte glycoprotein peptide along with TRAIL or programmed death-1 ligand. J Immunol 174:1888-97
11. Huang CC, Lee TJ, Chang PH et al. (2010) Desmoglein 3 is overexpressed in inverted papilloma and squamous cell carcinoma of sinonasal cavity. Laryngoscope 120:26-9
12. Ishii K, Lin C, Siegel DL et al. (2008) Isolation of pathogenic monoclonal antidesmoglein 1 human antibodies by phage display of pemphigus foliaceus autoantibodies. J Invest Dermatol 128:939-48
13. Jansen BJ, van Ruissen F, Cerneus S et al. (2003) Tumor necrosis factor related apoptosis inducing ligand triggers apoptosis in dividing but not in differentiating human epidermal keratinocytes. J Invest Dermatol 121:1433-9
14. Kalb ML, Glaser A, Stary G et al. (2012) TRAIL() human plasmacytoid dendritic cells kill tumor cells in vitro: Mechanisms of imiquimod-And IFN-Alpha-mediated antitumor reactivity. J Immunol 188:1583-91
15. Kedinger V, Muller S, Gronemeyer H (2011) Targeted expression of tumor necrosis factor-related apoptosis-inducing ligand TRAIL in skin protects mice against chemical carcinogenesis. Mol Cancer 10:34
16. Kothny-Wilkes G, Kulms D, Poppelmann B et al. (1998) Interleukin-1 protects transformed keratinocytes from tumor necrosis factor-related apoptosisinducing ligand. J Biol Chem 273:29247-53
17. Leverkus M, Neumann M, Mengling T et al. (2000) Regulation of tumor necrosis factor-related apoptosis-inducing ligand sensitivity in primary and transformed human keratinocytes. Cancer Res 60:553-9
18. Lunemann JD, Waiczies S, Ehrlich S et al. (2002) Death ligand TRAIL induces no apoptosis but inhibits activation of human (auto)antigen-specific T cells. J Immunol 168:4881-8
19. Martinez-Lostao L, Garcia-Alvarez F, Basanez G et al. (2010) Liposome-bound APO2L/TRAIL is an effective treatment in a rabbit model of rheumatoid arthritis. Arthritis Rheum 62:2272-82
20. Meier S, Guthe S, Kiefhaber T et al. (2004) Foldon, the natural trimerization domain of T4 fibritin, dissociates into a monomeric A-state form containing a stable beta-hairpin: Atomic details of trimer dissociation and local beta-hairpin stability from residual dipolar couplings. J Mol Biol 344:1051-69
21. Niederkorn JY (2006) See no evil, hear no evil, do no evil: The lessons of immune privilege. Nat Immunol 7:354-9
22. Payne AS, Ishii K, Kacir S et al. (2005) Genetic and functional characterization of human pemphigus vulgaris monoclonal autoantibodies isolated by phage display. J Clin Invest 115:888-99
23. Phillips TA, Ni J, Pan G et al. (1999) TRAIL (Apo-2L) and TRAIL receptors in human placentas: Implications for immune privilege. J Immunol 162:6053-9
24. Qin J, Chaturvedi V, Bonish B et al. (2001) Avoiding premature apoptosis of normal epidermal cells. Nat Med 7:385-6
25. Schneider B, Munkel S, Krippner-Heidenreich A et al. (2010) Potent antitumoral activity of TRAIL through generation of tumor-Targeted singlechain fusion proteins. Cell Death Dis 1:e68
26. Solassol J, Burcia V, Costes V et al. (2010) Pemphigus vulgaris antigen mRNA quantification for the staging of sentinel lymph nodes in head and neck cancer. Br J Cancer 102:181-7
27. Thomas WD, Hersey P (1998) TNF-related apoptosis-inducing ligand (TRAIL) induces apoptosis in Fas ligand-resistant melanoma cells and mediates CD4 T cell killing of target cells. J Immunol 161:2195-200
28. Trabzuni D, Famulski KS, Ahmad M (2000) Functional analysis of tumour necrosis factor-Alpha-related apoptosis-inducing ligand (TRAIL): Cysteine-230 plays a critical role in the homotrimerization and biological activity of this novel tumoricidal cytokine. Biochem J 350(Pt 2): 505-10
29. Wang SH, Chen GH, Fan Y et al. (2009) Tumor necrosis factor-related apoptosis-inducing ligand inhibits experimental autoimmune thyroiditis by the expansion of CD4 D25 regulatory T cells. Endocrinology 150:2000-7
30. Yoldas B, Ozer C, Ozen O et al. (2011) Clinical significance of TRAIL and TRAIL receptors in patients with head and neck cancer. Head Neck 33:1278-84
31. Zhang XD, Franco A, Myers K et al. (1999) Relation of TNF-related apoptosisinducing ligand (TRAIL) receptor and FLICE-inhibitory protein expression to TRAIL-induced apoptosis of melanoma. Cancer Res 59:2747-53
32. Zhao L, Li W, Marshall C et al. (2009) Srcasm inhibits Fyn-induced cutaneous carcinogenesis with modulation of Notch1 and p53. Cancer Res 69: 9439-47